<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01223326</url>
  </required_header>
  <id_info>
    <org_study_id>2003/NAC</org_study_id>
    <secondary_id>PIUNA</secondary_id>
    <nct_id>NCT01223326</nct_id>
  </id_info>
  <brief_title>N-acetylcysteine to Reduce Ischemia/Reperfusion Injury in Liver Resection</brief_title>
  <official_title>A Randomized Controlled Trial of N-acetylcysteine to Reduce Ischemia/Reperfusion Injury in Liver Resection Performed Under Ischemic Preconditioning and Intermittent Portal Triad Clamping</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinica Universidad de Navarra, Universidad de Navarra</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clinica Universidad de Navarra, Universidad de Navarra</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study hypothesis: N-acetylcysteine (NAC) can reduce ischemia/reperfusion injury in liver
      resection performed under ischemic preconditioning and intermittent portal triad clamping.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      One of the most important factors in the pathophysiology of liver dysfunction after hepatic
      surgery is the cellular damage derived from the interruption of blood flood with reperfusion
      of the organ. N-acetylcysteine (NAC) has proved beneficial in several conditions involving
      oxidative damage. This study investigates the effects of NAC to reduce ischemia/reperfusion
      injury in liver resection performed under ischemic preconditioning and intermittent portal
      triad clamping.

      Methods: 46 ASA II-III patients scheduled to undergo liver resection where randomised to
      receive NAC (initial dose: 150 mg/Kg; and infusion of 50 mg/kg, from 30 minutes before the
      ischemia up to 60 minutes later to the reperfusion) or placebo in a phase IV clinical trial.
      Blood, hepatic and urinary markers were obtained at basal status and 1, 3 and 24 h post final
      reperfusion.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Laboratory results</measure>
    <time_frame>24 hours</time_frame>
    <description>Coagulation + cytolysis + cholestasis + lactic acid</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inflammation</measure>
    <time_frame>24 hours</time_frame>
    <description>Cytokines, adhesion molecules (P-selectin and ICAM-1) and nuclear factor kappaB (NF-kappaB). Circulating neutrophils/platelets. Oxidative stress of neutrophils and apoptosis.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Hepatectomy</condition>
  <condition>Reperfusion Injury</condition>
  <arm_group>
    <arm_group_label>N-acetylcysteine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous N-acetylcysteine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetylcysteine (NAC)</intervention_name>
    <description>NAC 150 mg/Kg; and infusion of 50 mg/kg, from 30 minutes before the ischemia up to 60 minutes later to the reperfusion</description>
    <arm_group_label>N-acetylcysteine</arm_group_label>
    <other_name>Flumil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Na Cl 0.9% infusion</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hepatectomy

        Exclusion Criteria:

          -  ASA 4

          -  Cirrhosis

          -  Creatinine &gt; 1.2 mg/dL

          -  Associate surgery (pancreatic or splenectomy)

          -  Intraoperative bleeding &gt; 2 L.

          -  Active infection of inflammatory disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pablo Monedero, M.D., Ph. D.</last_name>
    <role>Study Director</role>
    <affiliation>Clinica Universidad de Navarra</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 15, 2010</study_first_submitted>
  <study_first_submitted_qc>October 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2010</study_first_posted>
  <last_update_submitted>June 7, 2012</last_update_submitted>
  <last_update_submitted_qc>June 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acetylcysteine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Reperfusion Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

